Oppenheimer Maintains Outperform on MBX Biosciences, Raises Price Target to $80
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Trevor Allred maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $80.
Oppenheimer analyst Trevor Allred maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $38 to $80.